Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML-BFM 2012 trial in children and adolescents with acute myeloid leukemia
ISRCTN78830591Phase 3Terminated
- Sponsor
- Hannover Medical School
- Start
- Jul 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of clofarabine, etoposide, tioguanine, cytarabine, methotrexate and 1 more in acute myeloid leukemia (AML) (4 arms), sponsored by Hannover Medical School. Primary endpoints: Event-free survival and Disease-free survival. Started Jul 2013; status: terminated.
02
Drugs
clofarabineetoposidetioguaninecytarabinemethotrexate
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ISRCTN78830591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN78830591.